{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:21:34Z","timestamp":1778613694776,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd012151","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000}}],"reference-count":139,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012151.pub2","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T19:53:26Z","timestamp":1476734006000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus"],"prefix":"10.1002","volume":"2016","author":[{"given":"Bianca","family":"Hemmingsen","sequence":"first","affiliation":[{"name":"Herlev University Hospital; Department of Internal Medicine; Herlev Ringvej 75 Herlev Denmark DK-2730"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Peick","family":"Sonne","sequence":"additional","affiliation":[{"name":"Gentofte Hospital, University of Copenhagen; Center for Diabetes Research, Department of Medicine; Kildegaardsvej 28 Hellerup Denmark DK-2900"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Inti","family":"Metzendorf","sequence":"additional","affiliation":[{"name":"Institute of General Practice, Medical Faculty of the Heinrich-Heine-University D\u00fcsseldorf; Cochrane Metabolic and Endocrine Disorders Group; Moorenstr. 5 D\u00fcsseldorf Germany 40225"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Richter","sequence":"additional","affiliation":[{"name":"Institute of General Practice, Medical Faculty of the Heinrich-Heine-University D\u00fcsseldorf; Cochrane Metabolic and Endocrine Disorders Group; Moorenstr. 5 D\u00fcsseldorf Germany 40225"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD012151.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2796.2006.01633.x","article-title":"Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance","volume":"259","author":"Eriksson","year":"2006","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Lindblad U Lindberg G Mansson NO Ranstam J Tyrberg M Jansson S Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY) Diabetes, Obesity & Metabolism 2011 185 8","DOI":"10.1111\/j.1463-1326.2010.01331.x"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0003|cit3","unstructured":"Melander A Lindblad U Ranstam J The NEPI Antidiabetes Study (NANSY), a Scandinavian Complement to the DPP Study Diabetes 1999"},{"issue":"8","key":"10.1002\/14651858.CD012151.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1463-1326.2007.00759.x","article-title":"Retinopathy in subjects with impaired fasting glucose: the NANSY-Eye baseline report","volume":"10","author":"Tyrberg","year":"2008","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0011|cit5","unstructured":"Novartis clinical result database - NAVIGATOR www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=3223"},{"issue":"0","key":"10.1002\/14651858.CD012151.pub2-BIB0005|cit6","first-page":"A357","article-title":"Estimating diabetes risk in patients with impaired glucose tolerance and cardiovascular disease (CVD) or risk factors for CVD","volume":"60","author":"Bethel","year":"2011","journal-title":"Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0006|cit7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ahj.2008.05.017","article-title":"Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial","volume":"156","author":"Califf","year":"2008","journal-title":"American Heart Journal"},{"issue":"21","key":"10.1002\/14651858.CD012151.pub2-BIB0007|cit8","article-title":"Stroke in people with impaired glucose tolerance","volume":"124","author":"Califf","year":"2011","journal-title":"Circulation"},{"issue":"16","key":"10.1002\/14651858.CD012151.pub2-BIB0008|cit9","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1056\/NEJMoa1001122.","article-title":"Effect of nateglinide on the incidence of diabetes and cardiovascular events","volume":"362","author":"NAVIGATOR Study Group","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1002\/14651858.CD012151.pub2-BIB0009|cit10","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"NAVIGATOR Study Group","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0010|cit11","unstructured":"NCT00097786 Long-term study of nateglinide+valsartan to prevent or delay type II diabetes mellitus and cardiovascular complications (Navigator) clinicaltrials.gov\/ct2\/show\/NCT00097786"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.metabol.2003.11.016","article-title":"Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes","volume":"53","author":"Osei","year":"2004","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"6","key":"10.1002\/14651858.CD012151.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1464-5491.1992.tb01839.x","article-title":"Can life-styles of subjects with impaired glucose tolerance be changed? A feasibility study","volume":"9","author":"Page","year":"1992","journal-title":"Diabetic Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012151.pub2-BIB0014|cit14","first-page":"145","article-title":"'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance","volume":"86","author":"Page","year":"1993","journal-title":"The Quarterly Journal of Medicine"},{"issue":"363","key":"10.1002\/14651858.CD012151.pub2-BIB0015|cit15","first-page":"Abstract 31","article-title":"Short term effects (2 years) of oral treatment for diabetes in the borderline impairment of oral glucose tolerance test","volume":"10","author":"Eschwege E. French Study Group for Diabetes Epidemiology (A.F.E.D.I.A.)","year":"1974","journal-title":"Diabetologia"},{"issue":"5","key":"10.1002\/14651858.CD012151.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/BF01219646","article-title":"Effect of oral hypoglycaemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients","volume":"15","author":"Papoz","year":"1978","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/meta.2003.50068","article-title":"Low-dose oral glyburide reduces glucose production rates in patients with impaired fasting glucose","volume":"52","author":"Bavirti","year":"2003","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD012151.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00555504","article-title":"The influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycaemia","volume":"35","author":"Bitzen","year":"1988","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012151.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/03009738509178480","article-title":"Short-term treatment of glucose intolerance in middle-aged subjects by diet, exercise and sulfonylurea","volume":"90","author":"Cederholm","year":"1985","journal-title":"Upsala Journal of Medical Sciences"},{"issue":"1","key":"10.1002\/14651858.CD012151.pub2-BIB0020|cit20","first-page":"10","article-title":"The impact of treatment on insulin release and relative peripheral resistance during the oral glucose tolerance test. A study of noninsulin-dependent diabetes mellitus and glucose intolerance","volume":"12","author":"Cederholm","year":"1986","journal-title":"Diabete & Metabolisme"},{"issue":"3","key":"10.1002\/14651858.CD012151.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1253\/circj.CJ-11-1011","article-title":"Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients","volume":"76","author":"Kataoka","year":"2012","journal-title":"Circulation Journal"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0022|cit22","first-page":"A288","article-title":"No effect of exenatide or sitagliptin therapy on beta-cell secretory capacity in early type 2 diabetes","volume":"62","author":"Gudipaty","year":"2013","journal-title":"Diabetes"},{"issue":"9","key":"10.1002\/14651858.CD012151.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2337\/dc14-0398","article-title":"Effect of exenatide, sitagliptin, or glimepiride on beta-cell secretory capacity in early type 2 diabetes","volume":"37","author":"Gudipaty","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0024|cit24","unstructured":"NCT00775684 Effect of exenatide, sitagliptin or glimepiride on functional \u00df-cell mass clinicaltrials.gov\/ct2\/show\/NCT00775684"},{"issue":"6","key":"10.1002\/14651858.CD012151.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1507\/endocrj.49.649","article-title":"The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects","volume":"49","author":"Hirose","year":"2002","journal-title":"Endocrine Journal"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0026|cit26","article-title":"Visceral fat metabolic activity is independently associated with coronary artery inflammation in patients with impaired glucose intolerance or type 2 diabetes","volume":"130","author":"Igata","year":"2014","journal-title":"Circulation"},{"issue":"21","key":"10.1002\/14651858.CD012151.pub2-BIB0028|cit27","article-title":"Effects of pioglitazone versus glimepiride on abdominal fat glucose metabolism in patients with impaired glucose tolerance and\/or type 2 diabetes mellitus","volume":"126","author":"Kodama","year":"2012","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD012151.pub2-BIB0027|cit28","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2013-2920","article-title":"Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus","volume":"98","author":"Kodama","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD012151.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jcmg.2011.08.007","article-title":"Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET\/CT imaging study of carotid artery and ascending aorta","volume":"4","author":"Mizoguchi","year":"2011","journal-title":"JACC. Cardiovascular Imaging"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0030|cit30","unstructured":"NCT00722631 Anti-inflammatory effects of pioglitazone clinicaltrials.gov\/ct2\/show\/NCT00722631"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0031|cit31","unstructured":"Nitta Y Tahara N Honda A Tahara A Kodama N Mizoguchi M Effects of pioglitazone on coronary arterial inflammation evaluated by serial FDG-PET\/CT in patients with impaired glucose tolerant or type 2 diabetes Circulation. Conference: American Heart Association 2012"},{"issue":"11","key":"10.1002\/14651858.CD012151.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jcmg.2013.09.004","article-title":"Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET\/CT imaging","volume":"6","author":"Nitta","year":"2013","journal-title":"JACC. Cardiovascular Imaging"},{"issue":"5","key":"10.1002\/14651858.CD012151.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1089\/rej.2013.1434","article-title":"Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes","volume":"16","author":"Tahara","year":"2013","journal-title":"Rejuvenation Research"},{"issue":"3","key":"10.1002\/14651858.CD012151.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-8227(97)00045-4","article-title":"Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus","volume":"36","author":"Inoue","year":"1997","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/dmrr.542","article-title":"No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes","volume":"21","author":"Johanson","year":"2005","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0036|cit36","first-page":"444","article-title":"[Effects of mitiglinide in treatment of impaired glucose tolerance]","volume":"63 Suppl 2","author":"Katahira","year":"2005","journal-title":"Nihon Rinsho. Japanese Journal of Clinical Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012151.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1463-1326.2001.00166.x","article-title":"The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose","volume":"3","author":"Lindblad","year":"2001","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD012151.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1055\/s-0028-1082327","article-title":"Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose-load endothelial function in insulin resistant individuals: is stimulation of first phase insulin secretion beneficial for the endothelial function?","volume":"40","author":"Major-Pedersen","year":"2008","journal-title":"Hormone and Metabolic Research"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0039|cit39","unstructured":"NCT00259168 Insulin resistance and vessel function after meals: does early intervention make a difference? clinicaltrials.gov\/ct2\/show\/NCT00259168?term=NCT00259168&rank=1"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0040|cit40","unstructured":"NCT00744965 Treatment of mild gestational diabetes with glyburide versus placebo clinicaltrials.gov\/ct2\/show\/NCT00744965"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0041|cit41","unstructured":"NCT01563120 A comparison between two oral hypoglycemics - metformin and glybenclamide for the treatment of gestational diabetes mellitus clinicaltrials.gov\/show\/NCT01563120"},{"issue":"1","key":"10.1002\/14651858.CD012151.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00315134","article-title":"Acute effect of glipizide on glucose tolerance in obesity and diabetes mellitus (NIDDM)","volume":"40","author":"Pontiroli","year":"1991","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0043|cit43","first-page":"32","article-title":"Improvement of glucose tolerance by minimal doses of glipizide in obese subjects with different degrees of glucose intolerance","volume":"26","author":"Pontiroli","year":"1992","journal-title":"Hormone and Metabolic Research. Supplement Series"},{"issue":"23","key":"10.1002\/14651858.CD012151.pub2-BIB0044|cit44","first-page":"913","article-title":"[Effect of glibenclamide therapy on carbohydrate and lipid metabolism and insulin secretion in patients with glucose tolerance disorders : a 5-year study]","volume":"36","author":"Ratzmann","year":"1981","journal-title":"Zeitschrift fur die Gesamte Innere Medizin und ihre Grenzgebiete"},{"issue":"2","key":"10.1002\/14651858.CD012151.pub2-BIB0045|cit45","first-page":"87","article-title":"The effect of long-term glibenclamide treatment on glucose tolerance, insulin secretion and serum lipids in subjects with impaired glucose tolerance","volume":"9","author":"Ratzmann","year":"1983","journal-title":"Diab\u00e8te & M\u00e9tabolisme"},{"issue":"12","key":"10.1002\/14651858.CD012151.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2337\/diacare.25.12.2141","article-title":"Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population","volume":"25","author":"Saloranta","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2840-5-9","article-title":"Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance","volume":"5","author":"Schmoelzer","year":"2006","journal-title":"Cardiovascular Diabetology"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD012151.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0026-0495(97)90318-8","article-title":"The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose","volume":"46","author":"Dyson","year":"1997","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD012151.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0026-0495(97)90317-6","article-title":"The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non-insulin-dependent diabetes prevention trial","volume":"46","author":"Hammersley","year":"1997","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD012151.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0026-0495(97)90319-X","article-title":"The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose","volume":"46","author":"Karunakaran","year":"1997","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"5","key":"10.1002\/14651858.CD012151.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2337\/db05-1200","article-title":"Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study","volume":"55","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes"},{"issue":"12","key":"10.1002\/14651858.CD012151.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012151.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2337\/diacare.20.7.1183","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus","volume":"20","author":"The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"1997","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012151.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/diacare.26.2007.S5","article-title":"Report of the expert committee on the diagnosis and classification of diabetes mellitus","volume":"26","author":"Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"2003","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012151.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2337\/dc08-S012","article-title":"Standards of medical care in diabetes - 2008","volume":"31","author":"American Diabetes Association","year":"2008","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012151.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012151.pub2-BIB0057|cit57","first-page":"S1","article-title":"Standards of medical care in diabetes-2015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1002\/14651858.CD012151.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012151.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1345\/aph.1E081","article-title":"Pharmacologic prevention or delay of type 2 diabetes mellitus","volume":"39","author":"Anderson","year":"2005","journal-title":"Annals of Pharmacotherapy"},{"issue":"2","key":"10.1002\/14651858.CD012151.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00254832","article-title":"The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes","volume":"22","author":"Keen","year":"1982","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/pon.3205","article-title":"Designing psycho-oncology randomised trials and cluster randomised trials: variance components and intra-cluster correlation of commonly used psychosocial measures","volume":"22","author":"Bell","year":"2013","journal-title":"Psycho-oncology"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2046-4053-2-36","article-title":"Are systematic reviews up-to-date at the time of publication?","volume":"2","author":"Beller","year":"2013","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0063|cit63","unstructured":"Bhardwaj A Agarwal V Phung OJ Baker WL Tongbram V Coleman CI Can oral hypoglycemic agents restore normoglycemia in individuals with insulin resistance? Diabetes. Conference: 70th Scientific Sessions of the American Diabetes Association Orlando, FL United States 2010"},{"issue":"2","key":"10.1002\/14651858.CD012151.pub2-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004654.pub2","article-title":"Meglitinide analogues for type 2 diabetes mellitus","author":"Black","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012151.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1262-3636(07)70257-4","article-title":"Meglitinide analogues: a review of clinical data focused on recent trials","volume":"32","author":"Blickle","year":"2006","journal-title":"Diabetes & Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD012151.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2337\/diab.45.11.1585","article-title":"Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects","volume":"45","author":"Groop","year":"1996","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2014.56.7503","article-title":"Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial","volume":"32","author":"Boutron","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012151.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0069|cit69","unstructured":"Centers for Disease Control and Prevention 2014 National Diabetes Statistics Report www.cdc.gov\/diabetes\/data\/statistics\/2014statisticsreport.html"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.metabol.2005.10.003","article-title":"The utility of fasting glucose for detection of prediabetes","volume":"55","author":"Cheng","year":"2006","journal-title":"Metabolism: Clinical and Experimental"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0071|cit71","unstructured":"clinicaltrials.gov\/ct2\/results?term=prediabetes+drugs&Search=Search"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jrsm.1090","article-title":"Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool","volume":"5","author":"Corbett","year":"2014","journal-title":"Research Synthesis Methods"},{"issue":"27","key":"10.1002\/14651858.CD012151.pub2-BIB0073|cit73","first-page":"iii-x, 1-173","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"Deeks","year":"2003","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0026-0495(89)90129-7","article-title":"Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake","volume":"38","author":"DeFronzo","year":"1989","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"6","key":"10.1002\/14651858.CD012151.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"9702","key":"10.1002\/14651858.CD012151.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0077|cit77","unstructured":"Diabetes.co.uk Convert whole blood results to plasma readings www.diabetes.co.uk\/whole-blood-readings-to-plasma-converter.html"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0078|cit78","unstructured":"Diabetes.co.uk Blood sugar converter www.diabetes.co.uk\/blood-sugar-converter.html"},{"issue":"5","key":"10.1002\/14651858.CD012151.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2337\/dc07-1868","article-title":"Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial","volume":"31","author":"Dagenais","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0080|cit80","unstructured":"Drugs.com Glimepiride www.drugs.com\/pro\/glimepiride.html"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0081|cit81","unstructured":"Drugs.com Gliclazide 80 mg tablets www.drugs.com\/uk\/gliclazide-80-mg-tablets-leaflet.html"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2337\/dc13-2195","article-title":"Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis","volume":"37","author":"Dunkley","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1471-2288-14-49","article-title":"Bias, precision and statistical power of analysis of covariance in the analysis of randomized trials with baseline imbalance: a simulation study","volume":"14","author":"Egbewale","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"18","key":"10.1002\/14651858.CD012151.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012151.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MAJ.0000000000000223","article-title":"Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice","volume":"348","author":"Gosmanov","year":"2014","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0086|cit86","unstructured":"GRADE Working Group, McMaster University GRADEproGDT 2015"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00002018-200022040-00004","article-title":"Comparative tolerability of sulphonylureas in diabetes mellitus","volume":"22","author":"Harrower","year":"2000","journal-title":"Drug Safety"},{"issue":"5","key":"10.1002\/14651858.CD012151.pub2-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012204","article-title":"Dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012106.pub2","article-title":"Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD012151.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD012151.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"Journal of the Royal Statistical Society: Series A (Statistics in Society)"},{"issue":"9","key":"10.1002\/14651858.CD012151.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/sim.4088","article-title":"Sequential methods for random-effects meta-analysis","volume":"30","author":"Higgins","year":"2011","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0094|cit94","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD012151.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/1741826711421687","article-title":"Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials","volume":"18","author":"Hopper","year":"2011","journal-title":"European Journal of Cardiovascular Prevention and Rehabilitation"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.1503\/cmaj.120744","article-title":"Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors","volume":"185","author":"Hr\u00f3bjartsson","year":"2013","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0098|cit98","unstructured":"International Conference on Harmonisation Expert Working Group International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice \/\/1997 CFR & ICH Guidelines PA 19063-2043 USA: Barnett International\/PAREXEL, 1997"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0099|cit99","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2013"},{"issue":"7","key":"10.1002\/14651858.CD012151.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc09-9033","article-title":"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes","volume":"32","author":"International Expert Committee","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD012151.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.2337\/diabetes.51.7.2170","article-title":"Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S","volume":"51","author":"Jensen","year":"2002","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"issue":"7","key":"10.1002\/14651858.CD012151.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"12","key":"10.1002\/14651858.CD012151.pub2-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub2","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jama.2009.1242","article-title":"Comparison of registered and published primary outcomes in randomized controlled trials","volume":"302","author":"Mathieu","year":"2009","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1517\/14656566.2.4.699","article-title":"Clinical review of glimepiride","volume":"2","author":"McCall","year":"2001","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD012151.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2337\/diacare.25.10.1845","article-title":"Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study","volume":"25","author":"Meigs","year":"2002","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD012151.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00125-013-2902-4","article-title":"Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis","volume":"56","author":"Morris","year":"2013","journal-title":"Diabetologia"},{"issue":"12","key":"10.1002\/14651858.CD012151.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2337\/diab.28.12.1039","article-title":"Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group","volume":"28","author":"National Diabetes Data Group","year":"1979","journal-title":"Diabetes"},{"issue":"9","key":"10.1002\/14651858.CD012151.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1463-1326.2012.01604.x","article-title":"Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis","volume":"14","author":"Pantalone","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"15","key":"10.1002\/14651858.CD012151.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1517\/14656566.2013.834048","article-title":"Mitiglinide for type 2 diabetes treatment","volume":"14","author":"Phillippe","year":"2013","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1345\/aph.1Q554","article-title":"Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta-analysis","volume":"46","author":"Phung","year":"2012","journal-title":"Annals of Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD012151.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"580-93; discuss","DOI":"10.1016\/S0197-2456(97)00051-2","article-title":"Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis","volume":"18","author":"Pogue","year":"1997","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0116|cit116","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"issue":"16","key":"10.1002\/14651858.CD012151.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/sim.5726","article-title":"Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data","volume":"32","author":"Riley","year":"2013","journal-title":"Statistics in Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012151.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-157-9-201211060-00003","article-title":"Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study","volume":"157","author":"Roumie","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012151.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2337\/diab.29.1.41","article-title":"Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation","volume":"29","author":"Sartor","year":"1980","journal-title":"Diabetes"},{"issue":"15","key":"10.1002\/14651858.CD012151.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","article-title":"Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study","volume":"32","author":"Schramm","year":"2011","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD012151.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/11207600-000000000-00000","article-title":"Repaglinide: a review of its use in type 2 diabetes mellitus","volume":"72","author":"Scott","year":"2012","journal-title":"Drugs"},{"issue":"5","key":"10.1002\/14651858.CD012151.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-154-5-201103010-00004","article-title":"Racial differences in glycemic markers: a cross-sectional analysis of community-based data","volume":"154","author":"Selvin","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2337\/diab.25.12.1129","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide","volume":"25","author":"The University Group Diabetes Program","year":"1976","journal-title":"Diabetes"},{"issue":"9131","key":"10.1002\/14651858.CD012151.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"9131","key":"10.1002\/14651858.CD012151.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0128|cit128","first-page":"CD005061","article-title":"Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose","volume":"4","author":"Laar","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/epirev\/mxr002","article-title":"Predisease: when does it make sense?","volume":"33","author":"Viera","year":"2011","journal-title":"Epidemiologic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012151.pub2-BIB0130|cit130","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000009.pub4","article-title":"Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate","author":"Vist","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012151.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD012151.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0133|cit133","volume-title":"Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus","author":"World Health Organization","year":"1999"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0134|cit134","unstructured":"World Health Organization\/ International Diabetes Federation Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO\/IDF consultation www.idf.org\/webdata\/docs\/WHO_IDF_definition_diagnosis_of_diabetes.pdf"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0135|cit135","first-page":"451","article-title":"Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"1","key":"10.1002\/14651858.CD012151.pub2-BIB0136|cit136","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"7644","key":"10.1002\/14651858.CD012151.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012151.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"g4485","DOI":"10.1136\/bmj.g4485","article-title":"The epidemic of pre-diabetes: the medicine and the politics","volume":"349","author":"Yudkin","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD012151.pub2-BIB0139|cit139","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012151","article-title":"Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012151.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T15:18:28Z","timestamp":1654528708000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012151.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Metabolic and Endocrine Disorders Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":139,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012151.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,17]]}}}